JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan International Research Enhanced Equity ETF
JIRE
|
+$4.16B |
| 2 |
Microsoft
MSFT
|
+$2.29B |
| 3 |
Amazon
AMZN
|
+$2B |
| 4 |
UnitedHealth
UNH
|
+$1.76B |
| 5 |
iShares 7-10 Year Treasury Bond ETF
IEF
|
+$1.42B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan BetaBuilders Europe ETF
BBEU
|
+$4.61B |
| 2 |
Vanguard Short-Term Bond ETF
BSV
|
+$1.58B |
| 3 |
State Street Financial Select Sector SPDR ETF
XLF
|
+$689M |
| 4 |
iShares 0-1 Year Treasury Bond ETF
SHV
|
+$659M |
| 5 |
Invesco QQQ Trust
QQQ
|
+$647M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 15.03% |
| 2 | Healthcare | 12.52% |
| 3 | Financials | 10.5% |
| 4 | Consumer Discretionary | 7.88% |
| 5 | Industrials | 7.32% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2951
Compass
COMP
$10.2B
| $3.52M | ﹤0.01% |
973,944
+852,144
| +700% | +$4.66M |
|
|
NVTA
2952
DELISTED
Invitae Corporation
NVTA
| $3.52M | ﹤0.01% |
1,440,962
+148,648
| +12% | +$657K |
|
2953
Apogee Enterprises
APOG
$897M
| $3.5M | ﹤0.01% |
89,243
-3,079
| -3% | -$132K |
|
2954
PUT
Marvell Technology
MRVL
$199B
| $3.5M | ﹤0.01% |
80,300
+40,000
| +99% | +$2.27M |
|
2955
BridgeBio Pharma
BBIO
$16.4B
| $3.49M | ﹤0.01% |
384,080
-364,026
| -49% | -$3.04M |
|
|
CTLT
2956
CALL
DELISTED
CATALENT, INC.
CTLT
| $3.49M | ﹤0.01% |
+32,500
| New | +$3.31M |
|
|
CTLT
2957
PUT
DELISTED
CATALENT, INC.
CTLT
| $3.49M | ﹤0.01% |
+32,500
| New | +$3.31M |
|
2958
John B. Sanfilippo & Son
JBSS
$989M
| $3.49M | ﹤0.01% |
48,094
-1,264
| -3% | -$96.6K |
|
2959
Fiverr
FVRR
$311M
| $3.48M | ﹤0.01% |
101,345
+83,374
| +464% | +$3.96M |
|
|
EVOJ
2960
DELISTED
Evo Acquisition Corp. Class A Common Stock
EVOJ
| $3.47M | ﹤0.01% |
355,458
-1,140
| -0.3% | -$11.2K |
|
2961
Weatherford International
WFRD
$6.6B
| $3.45M | ﹤0.01% |
162,854
+23,285
| +17% | +$741K |
|
|
EPWR
2962
DELISTED
Empowerment & Inclusion Capital I Corp.
EPWR
| $3.44M | ﹤0.01% |
350,000
-200,000
| -36% | -$1.96M |
|
2963
Pacific Biosciences
PACB
$357M
| $3.44M | ﹤0.01% |
778,424
-237,395
| -23% | -$1.44M |
|
2964
Lyell Immunopharma
LYEL
$347M
| $3.44M | ﹤0.01% |
26,359
+439
| +2% | +$44.9K |
|
2965
CALL
Nike
NKE
$61.2B
| $3.43M | ﹤0.01% |
33,600
-55,900
| -62% | -$6.61M |
|
2966
PUT
Datadog
DDOG
$90.6B
| $3.43M | ﹤0.01% |
36,000
-14,000
| -28% | -$1.54M |
|
|
MTAL
2967
DELISTED
Metals Acquisition
MTAL
| $3.42M | ﹤0.01% |
349,500
-50,500
| -13% | -$499K |
|
2968
CALL
CME Group
CME
$94.3B
| $3.42M | ﹤0.01% |
16,700
-29,400
| -64% | -$6.23M |
|
|
AYX
2969
DELISTED
Alteryx Inc
AYX
| $3.42M | ﹤0.01% |
70,583
+18,311
| +35% | +$1.1M |
|
|
FMIV
2970
DELISTED
Forum Merger IV Corporation Class A Common stock
FMIV
| $3.42M | ﹤0.01% |
349,785
+299,785
| +600% | +$2.93M |
|
|
SP
2971
DELISTED
SP Plus Corporation
SP
| $3.41M | ﹤0.01% |
111,133
-2,202
| -2% | -$66.5K |
|
|
BVH
2972
DELISTED
Bluegreen Vacations Holding Corporation
BVH
| $3.41M | ﹤0.01% |
136,730
+100,521
| +278% | +$2.66M |
|
2973
Federal Signal
FSS
$7.71B
| $3.41M | ﹤0.01% |
95,834
-15,327
| -14% | -$527K |
|
2974
Healthcare Services Group
HCSG
$1.43B
| $3.41M | ﹤0.01% |
195,700
+74,104
| +61% | +$1.28M |
|
2975
Cardlytics
CDLX
$24.7M
| $3.4M | ﹤0.01% |
15,244
-195,171
| -93% | -$65.4M |
|
Similar funds
JP Morgan Chase's Q2 2022 Portfolio in Review
As of Q2 2022, JP Morgan Chase held 7,270 positions worth $718B, down 14% from $830B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
JP Morgan Chase's Q2 2022 filing shows 568 new, 2,561 increased, 2,729 reduced and 610 closed positions. Its largest new stake was JPMorgan International Research Enhanced Equity ETF: 85,906,762 shares worth $4.15B. The largest sale was JPMorgan BetaBuilders Europe ETF, an estimated $4.61B.
By sector, the portfolio is most concentrated in Technology at 15% of assets, down from 16% a quarter earlier, followed by Healthcare and Financials.
- JP Morgan Chase's largest Q2 2022 buy was JPMorgan International Research Enhanced Equity ETF: 85,906,762 shares worth $4.15B.
- JP Morgan Chase added most to Microsoft in Q2 2022, an estimated $2.29B increase.
- JP Morgan Chase's biggest Q2 2022 reduction was JPMorgan BetaBuilders Europe ETF, cutting an estimated $4.61B.
- JP Morgan Chase fully exited Cerner Corp in Q2 2022, selling an estimated $608M.
- JP Morgan Chase's ten largest holdings make up 18% of its $718B portfolio in Q2 2022.
- JP Morgan Chase opened 568 new positions and closed 610 in Q2 2022.
- JP Morgan Chase's portfolio value fell 14% quarter-over-quarter to $718B.
Based on JP Morgan Chase's 13F filing for Q2 2022, filed 11 Aug 2022.